Q2 2025 Highlights - Sales reached $877 million, a 12% increase overall, with 9% organic growth[6] - Operating Income increased by 20% to $160 million, resulting in a 130 bps year-over-year margin expansion to 183%[6] - Diluted EPS increased by 21% to $323[6] - Free Cash Flow increased by 17% to $117 million[6] - New Orders totaled $1 billion, resulting in a book-to-bill ratio greater than 11x, and backlog increased by 12% year-to-date[6] Full-Year 2025 Guidance - Total Sales growth is projected to increase by 9% - 10% due to strengthening A&D market growth[6] - Operating Income growth is targeted at 15% - 18%, with an Operating Margin of 185% - 187%, up 100 - 120 bps year-over-year[6] - The company is on track to deliver high-teens EPS growth (up 16% - 19%) and strong FCF generation (~108% conversion)[6] End Market Sales Growth Guidance - Aerospace Defense is expected to grow by 7% - 9%, contributing to 19% of sales[10] - Naval Defense is expected to grow by 7% - 9%, contributing to 26% of sales[10] - Commercial Aerospace is expected to grow by 13% - 15%, contributing to 13% of sales[10] - Power & Process is expected to grow by 16% - 18%, contributing to 19% of sales[10]

Financial Data and Key Metrics Changes - Second quarter revenue totaled $222.9 million, reflecting a 5.4% increase in organic revenue and a 7.6% increase in total revenue compared to Q2 2024 [6][28] - Adjusted EBITDA for the second quarter was $51.2 million, up 4.9% year-over-year [7][29] - Adjusted EPS increased by 10% to $0.11 per share, with a note that excluding certain shares, adjusted EPS would have been $0.13 [30] Business Line Data and Key Metrics Changes - The Nuclear and Safety segment revenue grew 5.8% to $141.7 million, with organic revenue growth of 2.9% [31] - The Medical segment revenue grew 10.9% to $81.2 million, with organic revenue growth of 10.1% [33] - Adjusted EBITDA for the Medical segment was $30.1 million, up nearly 20% year-over-year, with margins increasing approximately 280 basis points [34] Market Data and Key Metrics Changes - Year-to-date, nuclear power orders grew 10%, reflecting strong momentum in the North American and French nuclear power installed base [25] - Approximately $9 million in small modular reactor (SMR) related orders were booked year-to-date, with a total of $17 million in aggregate SMR orders historically disclosed [10][21] - The project pipeline for 2026 is building, indicating a positive outlook for future orders [70] Company Strategy and Development Direction - The company is focusing on increasing adjusted free cash flow generation, optimizing capital structure, and pursuing mergers and acquisitions (M&A) [4][5] - The acquisition of Certrek is expected to enhance growth through commercial synergies and support the nuclear power sector's objectives [21][52] - The company is actively introducing new products and technologies, such as the Vital platform and LightLink technology, to meet customer needs and improve operational efficiency [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the nuclear power sector, citing increasing capital budgets and modernization opportunities within the installed fleet [12][60] - The company anticipates double-digit organic growth from the nuclear power end market in 2025, reflecting a bullish outlook [39] - Management is cautious about the SMR market but acknowledges accelerating activity and engagement with key players [80] Other Important Information - The company successfully completed a $400 million convertible note offering and refinanced its term loan, improving its capital structure [8][36] - Adjusted free cash flow for Q2 was $6 million, with expectations to reach $95 million to $115 million for the full year [9][40] Q&A Session Summary Question: Can you quantify the number of new nuclear opportunities compared to two years ago? - Management noted that both the number of new projects and their desired timing are accelerating, with significant discussions around new utility-scale nuclear projects in the US [44][47] Question: Can you elaborate on the Surtrac acquisition and its synergies? - The acquisition is seen as a strategic fit, with Surtrac's strong revenue from nuclear power customers and significant data assets that can enhance regulatory processes [48][50] Question: How bankable is the growth rate from the installed base? - Management indicated that the fundamentals are strong, with increasing capital budgets and modernization efforts expected to drive growth [60][62] Question: Is there a possibility of a $300 million order quarter? - Management expressed that while unlikely, they are optimistic about their position in the opportunity set and expect to win their fair share of large orders [66][68] Question: What is the outlook for margins in the nuclear segment? - Management reassured that project margins are expected to align with initial expectations, despite some fluctuations in accounting [72][74] Question: How resilient are the medical and lab businesses moving forward? - Management highlighted that the medical markets have held up well, driven by a higher proportion of Medicare reimbursements and efficiency improvements [84][85] Question: What is the current supply and demand dynamic in nuclear medicine? - Demand is growing faster than supply, with improved margin profiles due to pricing power and a shift towards software sales [88] Question: What is the growth from conventional nuclear power excluding SMR? - Management confirmed positive order growth in the nuclear power segment, even when excluding SMR orders [91]

Financial Data and Key Metrics Changes - Second quarter revenue totaled $222.9 million, reflecting a 5.4% increase in organic revenue and a 7.6% increase in total revenue compared to Q2 2024 [6][27] - Adjusted EBITDA for Q2 was $51.2 million, up 4.9% year-over-year, with adjusted EPS increasing by 10% to $0.11 per share [6][30] - Adjusted free cash flow generated in Q2 was $6 million, representing an 11% conversion of adjusted EBITDA [8] Business Line Data and Key Metrics Changes - The Nuclear and Safety segment revenue grew 5.8% to $141.7 million, with organic revenue growth of 2.9% [31] - The Medical segment revenue increased by 10.9% to $81.2 million, with organic revenue growth of 10.1% [33] - Adjusted EBITDA for the Medical segment was $30.1 million, up nearly 20% year-over-year, with margins increasing approximately 280 basis points [34] Market Data and Key Metrics Changes - Year-to-date nuclear power orders grew 10%, with significant engagement in the North American and French nuclear power installed base [25] - Approximately $9 million in small modular reactor (SMR) related orders were booked year-to-date, indicating accelerating growth in this sector [10] - The project pipeline for 2026 is building, with expectations for continued growth in the nuclear power market [69] Company Strategy and Development Direction - The company is focusing on increasing adjusted free cash flow generation, optimizing capital structure, and pursuing mergers and acquisitions, including the recent acquisition of Certrek [4][5] - There is a bullish outlook for the nuclear power sector, with expectations for double-digit organic growth in 2025 [39] - The company is actively introducing new products and enhancing its digital offerings, such as the Vital platform for real-time monitoring and data collection [17][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing momentum in the nuclear power sector and the opportunities presented by modernization and life extensions of existing reactors [12][14] - The company is cautious about the SMR market but acknowledges the acceleration in activity and engagement with key players [78] - Management is closely monitoring the medical segment's performance amid budgetary uncertainties but has not seen significant negative impacts yet [84] Other Important Information - The company raised and tightened key 2025 guidance metrics, including total revenue growth and adjusted EBITDA, while slightly lowering organic revenue growth expectations for the labs and research business [38] - The acquisition of Certrek is expected to enhance growth through commercial synergies and a strong position in the regulatory compliance solutions market [21][22] Q&A Session Summary Question: Can you quantify the number of new nuclear opportunities compared to two years ago? - Management noted that both the number and timing of new projects are accelerating, with significant discussions around new utility-scale nuclear projects in the US [45][48] Question: Can you elaborate on the Surtrac acquisition and its synergies? - The Surtrac acquisition is seen as a unique asset with strong revenue and margin profiles, and it aligns with the company's focus on nuclear power and digital solutions [49][53] Question: How bankable is the growth rate from the installed base? - Management indicated that the fundamentals for nuclear power are strong, with increasing capital budgets and modernization efforts expected to drive growth [60][62] Question: What is the outlook for the $350 million order pipeline? - Management expects to win a fair share of the opportunities in the pipeline, although some government-related orders may shift to the right [66][69] Question: Are there lingering margin issues from project cost increases? - Management clarified that while project costs can impact margins in the short term, they expect to achieve the margin rates initially anticipated for the project [71] Question: Will the SMR orders become a more meaningful part of the order ramp-up? - Management remains cautious but acknowledges that SMR activity has accelerated faster than expected, with ongoing engagement with key players [78][80] Question: How resilient is the medical business amid funding uncertainties? - Management has not seen significant negative impacts on the medical segment and believes their solutions align well with the need for efficiency in radiation therapy [84][86]

Core Insights - Cameco, a leading uranium miner, has seen its stock price surge approximately 250% over the past three years, significantly outperforming the S&P 500, which rose 60% during the same period [1] Company Overview - Cameco is based in Canada and operates uranium mines and mills in Canada, the U.S., and Kazakhstan, accounting for roughly 17% of the world's uranium production in 2024, making it the second-largest uranium miner after Kazatomprom [2] Historical Performance - From 2011 to 2021, Cameco's annual revenue declined from $2.41 billion to $1.18 billion, with no revenue growth during that decade, primarily due to the aftermath of the Fukushima disaster in 2011, which led to a global drop in uranium prices [4] - Uranium's spot price fell from over $70 per pound before the Fukushima disaster to below $20 in 2017, forcing Cameco to suspend operations at its largest mines and reduce production [5] Recent Recovery - Between 2021 and 2024, Cameco's revenue experienced a compound annual growth rate (CAGR) of 29% in Canadian dollar terms, with gross margins expanding into double digits over the past two years [6] - Revenue growth rates were reported at 27% in 2022, 39% in 2023, and 21% in 2024 [7] Market Dynamics - The recovery in Cameco's performance was driven by a significant increase in uranium spot prices, which rose from $29.63 in January 2021 to $78.50 in June 2024, prompting the company to restart mining operations at McArthur River and Key Lake in 2022 [8] - Several factors contributed to the rise in uranium prices, including reduced global supply due to production cuts by Cameco and Kazatomprom, alongside increased demand as countries resumed nuclear energy projects [10] Strategic Developments - In late 2023, Cameco partnered with Brookfield Asset Management to acquire a 49% stake in Westinghouse Electric, a nuclear power plant designer and builder, which is expected to stabilize its core mining business [9] - Global challenges, such as sanctions on Russia and supply chain issues in Kazakhstan and Niger, have further tightened uranium supply, benefiting Cameco [11] Future Outlook - Analysts predict that uranium prices will continue to rise as demand outpaces supply, with the growth of cloud and AI data centers driving interest in next-generation nuclear energy solutions [12] - Cameco's stake in Global Laser Enrichment (GLE) could position it as a comprehensive provider in the nuclear power sector, with the International Atomic Energy Agency (IAEA) projecting a potential 2.5 times increase in global nuclear capacity from 2024 to 2050 [13] - From 2024 to 2027, analysts expect Cameco's revenue to grow at a CAGR of 8% in Canadian dollar terms, with adjusted EBITDA projected to grow at a CAGR of 16% [14]

Industry Overview - Nuclear energy is increasingly recognized as a vital solution for meeting the world's growing electricity demands and supporting the transition to cleaner power sources, providing a constant and reliable supply of clean energy [1][2] - The demand for clean electricity is driven by industrial expansion, urbanization, rising global temperatures, the development of AI-powered data centers, and the adoption of electric vehicles [4] Investment Potential - Nuclear energy-related stocks, such as Duke Energy Corporation, Dominion Energy, and Constellation Energy Corporation, are becoming attractive investment options due to their ability to deliver steady output compared to other clean energy sources [2][6] - The International Energy Agency (IEA) projects that annual investment in nuclear energy will exceed $150 billion by 2030, up from $65 billion, with installed nuclear capacity potentially exceeding 1,000 gigawatts by 2050 [3] Company Insights Duke Energy - Duke Energy operates 11 nuclear units capable of producing nearly 10,700 megawatts of clean electricity, with nuclear power accounting for 27.5% of its total electricity output in 2024 [8] - The company plans to expand its nuclear capacity by nearly 250 megawatts by 2031 and has secured agreements to monetize over $500 million in nuclear production tax credits [9] - Duke Energy received approval to operate its Oconee Nuclear Station for another 20 years and is pursuing license renewals for all its reactors [10][11] Dominion Energy - Dominion Energy owns four nuclear power stations, generating nearly 40% of its total production, and is evaluating next-generation nuclear technologies, including small modular reactors (SMRs) [12][13] - The company aims to achieve net-zero carbon emissions by 2050, with nuclear power serving as a consistent, carbon-free solution [14] Constellation Energy - Constellation Energy is the largest nuclear power plant operator in the U.S., accounting for around 10% of the nation's total clean energy production [15] - The company has secured multiple uranium supply contracts extending through the 2030s to ensure long-term nuclear fuel security and is modernizing its nuclear plants to improve performance [16] - Constellation Energy is investing to expand its nuclear capacity and is evaluating the addition of up to one gigawatt of new carbon-free energy capacity over the next 10 years [17]

Core Insights - Oklo's stock surged 28.2% this week, outperforming the S&P 500 and Nasdaq-100, which rose 4.3% and 6.2% respectively [1] - The company reported a Q1 2025 loss of $0.07 per share, significantly better than Wall Street's expectation of a $0.10 loss, and a substantial improvement from a $4.79 loss in Q1 2024 [2] - Oklo reaffirmed its full-year guidance and is on track to launch its first commercial small modular reactor (SMR) by late 2027 or early 2028 [4] Financial Performance - The Q1 2025 loss of $0.07 per share represents a major year-over-year improvement from the previous year's loss of $4.79 per share [2] - The company maintained its full-year guidance, indicating confidence in its financial outlook [2] Strategic Developments - Oklo completed drilling at the site for its future Aurora reactor, validating the site as safe and suitable for construction [4] - The appointment of Pat Schweiger as chief technology officer (CTO) is expected to enhance the company's capabilities in power engineering [5] Industry Outlook - CEO Jacob DeWitte noted strong momentum in both the industry and political landscape, which is expected to positively influence the company's future [2] - The leadership change with the addition of Schweiger is seen as a strategic move to bolster Oklo's position in the advanced nuclear technology market [5]